ArticleInternational journal of molecular sciences2012
Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(β-l-malic acid).
Article in International journal of molecular sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Nanotechnology in neurosurgery: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Pooled it
- Recent progress in small molecules targeting the acidic tumor microenvironment.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles.Drug design, development and therapy · 2026Review
- Article
- Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer.Pharmaceutics · 2023Review
- Small-Sized Co-Polymers for Targeted Delivery of Multiple Imaging and Therapeutic Agents.Nanomaterials (Basel, Switzerland) · 2021Review
- Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery.Medicinal research reviews · 2020Review
- High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma.Bioactive materials · 2020Article
- National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Visualization and design of the functional group distribution during statistical copolymerization.Nature communications · 2019Article
- Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.Targeted oncology · 2018Review
- Effect of Chemical Binding of Doxorubicin Hydrochloride to Gold Nanoparticles, Versus Electrostatic Adsorption, on the In Vitro Drug Release and Cytotoxicity to Breast Cancer Cells.Pharmaceutical research · 2018Article
- Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.Targeted oncology · 2017Review
- Cleavable PEGylation: a strategy for overcoming the "PEG dilemma" in efficient drug delivery.Drug delivery · 2017Review
- Advances in antibody-drug conjugates: A new era of targeted cancer therapy.Drug discovery today · 2017Review
- Covalent nano delivery systems for selective imaging and treatment of brain tumors.Advanced drug delivery reviews · 2017Review
- Polymalic Acid Tritryptophan Copolymer Interacts with Lipid Membrane Resulting in Membrane Solubilization.Journal of nanomaterials · 2017Article
- Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles.Journal of visualized experiments : JoVE · 2016Article
- Curcumin Targeted, Polymalic Acid-Based MRI Contrast Agent for the Detection of Aβ Plaques in Alzheimer's Disease.Macromolecular bioscience · 2015Article
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics.Bioscience reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Doxorubicin (DOX) is currently used in cancer chemotherapy to treat many tumors and shows improved delivery, reduced toxicity and higher treatment efficacy when being part of nanoscale delivery systems. However, a major drawback remains its toxicity to healthy tissue and the development of multi-drug resistance during prolonged treatment. This is why in our work we aimed to improve DOX delivery and reduce the toxicity by chemical conjugation with a new nanoplatform based on polymalic acid. For delivery into recipient cancer cells, DOX was conjugated via pH-sensitive hydrazone linkage along with polyethylene glycol (PEG) to a biodegradable, non-toxic and non-immunogenic nanoconjugate platform: poly(β-l-malic acid) (PMLA). DOX-nanoconjugates were found stable under physiological conditions and shown to successfully inhibit in vitro cancer cell growth of several invasive breast carcinoma cell lines such as MDA-MB-231 and MDA-MB- 468 and of primary glioma cell lines such as U87MG and U251.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.